Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype

OBJECTIVE: Determine whether a treatment effect of ibudilast on brain atrophy rate differs between participants with primary (PPMS) and secondary (SPMS) progressive multiple sclerosis. BACKGROUND: Progressive forms of MS are both associated with continuous disability progression. Whether PPMS and SP...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Andrew D., Fedler, Janel K., Yankey, Jon, Klingner, Elizabeth A., Ecklund, Dixie J., Goebel, Christopher V., Bermel, Robert A., Chase, Marianne, Coffey, Christopher S., Klawiter, Eric C., Naismith, Robert T., Fox, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818089/
https://www.ncbi.nlm.nih.gov/pubmed/33460301
http://dx.doi.org/10.1002/acn3.51251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818089/
https://www.ncbi.nlm.nih.gov/pubmed/33460301
http://dx.doi.org/10.1002/acn3.51251

Ejemplares similares